Ca2+ entry through reverse Na+/Ca2+ exchanger in NCI-H716, glucagon-like peptide-1 secreting cells

Glucagon like peptide-1 (GLP-1) released from enteroendocine L-cells in the intestine has incretin effects due to its ability to amplify glucose-dependent insulin secretion. Promotion of an endogenous release of GLP-1 is one of therapeutic targets for type 2 diabetes mellitus. Although the secretion...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Korean journal of physiology & pharmacology 2022, 26(3), , pp.219-225
Hauptverfasser: Choi, Kyung Jin, Hwang, Jin Wook, Kim, Se Hoon, Park, Hyung Seo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Glucagon like peptide-1 (GLP-1) released from enteroendocine L-cells in the intestine has incretin effects due to its ability to amplify glucose-dependent insulin secretion. Promotion of an endogenous release of GLP-1 is one of therapeutic targets for type 2 diabetes mellitus. Although the secretion of GLP-1 in response to nutrient or neural stimuli can be triggered by cytosolic Ca 2+ elevation, the stimulus-secretion pathway is not completely understood yet. Therefore, the aim of this study was to investigate the role of reverse Na + /Ca 2+ exchanger (rNCX) in Ca 2+ entry induced by muscarinic stimulation in NCI-H716 cells, a human enteroendocrine GLP-1 secreting cell line. Intracellular Ca 2+ was repetitively oscillated by the perfusion of carbamylcholine (CCh), a muscarinic agonist. The oscillation of cytosolic Ca 2+ was ceased by substituting extracellular Na + with Li + or NMG + . KB-R7943, a specific rNCX blocker, completely diminished CCh-induced cytosolic Ca 2+ oscillation. Type 1 Na + /Ca 2+ exchanger (NCX 1 ) proteins were expressed in NCI-H716 cells. These results suggest that rNCX might play a crucial role in Ca 2+ entry induced by cholinergic stimulation in NCI-H716 cells, a GLP-1 secreting cell line.
ISSN:1226-4512
2093-3827
DOI:10.4196/kjpp.2022.26.3.219